ProPhase Labs, Inc (NASDAQ:PRPH) is one of three emerging companies that will present at Proactive’s virtual investor conference on Tuesday, February 16.
Hosted by Proactive's Christine Corrado, the event kicks off on Tuesday at 1 PM ET.
SIGN-UP: Proactive One2One February 16
This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses.
ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements.
The company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States.
Most recently, ProPhase Labs announced that it has begun new saliva-based, viral RT-PCR multiplex-testing as a laboratory developed test classification. Emergency use authorization applications have been filed and confirmed by the US Food and Drug administration (FDA) for its two new testing methodologies.
The company said its testing integrates the Spectrum Solutions saliva self-collection system with a new, advanced multiplex qPCR platform for the simultaneous RNA detection of not only COVID-19 but also its viral mutations, as well as Influenza A, B, and more.
ProPhase Labs joins GreenBank Capital Inc and Algernon Pharmaceuticals Inc on the event roster.